Literature DB >> 23568855

Pulmonary function tests in idiopathic inflammatory myopathy: association with clinical parameters in children.

Adrienne Prestridge1, Gabrielle Morgan, Lori Ferguson, Chiang-Ching Huang, Lauren M Pachman.   

Abstract

OBJECTIVE: To determine the association of decreased lung function in children with idiopathic inflammatory myopathies (IIMs) with specific clinical parameters.
METHODS: This study of 38 children ages 6-23 years diagnosed with definite/probable IIM evaluated the association of myositis-specific/-associated antibodies (MSAs/MAAs), duration of untreated disease at diagnosis, Disease Activity Score for muscle (DAS-M), muscle-derived enzymes (aldolase, lactate dehydrogenase [LDH], aspartate transaminase, and creatine phosphokinase [CPK]), neopterin and von Willebrand factor antigen, and the Childhood Myositis Assessment Scale (CMAS) scores with data from pulmonary function testing (PFT).
RESULTS: Impaired PFTs were defined as total lung capacity (TLC) or diffusing capacity for carbon monoxide (DLCO) of <80% predicted. The PFTs documented that 37% of the children (14 of 38) had either decreased TLC or decreased DLCO; 5% (2 of 38) had both. Children with decreased TLC alone (7 [18%] of 38) were older both at the time of PFT and diagnosis, had anti-Jo-1 and anti-Scl-70 antibody, and had elevated levels of CPK and neopterin. Children with decreased DLCO alone (5 [13%] of 38) had a shorter duration of untreated disease at diagnosis, had higher DAS-M and total DAS, were positive for anti-Ro and anti-PL-12, had increased LDH, and had elevated levels of neopterin and aldolase, with low CMAS scores for items 1, 3, 10, 11, and 14.
CONCLUSION: Assessment of PFTs in children with IIMs should be considered, since more than one-third of patients were found to be impaired. The presence of MSAs/MAAs, an elevated serum neopterin level (mean ± SD 12.4 ± 9.6 nmoles/liter, normal value <10.5), older age at diagnosis, and shorter duration of untreated disease at diagnosis suggest the presence of potential lung pathology.
Copyright © 2013 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2013        PMID: 23568855     DOI: 10.1002/acr.22014

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  7 in total

Review 1.  Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.

Authors:  Jian-Qiang Wu; Mei-Ping Lu; Ann M Reed
Journal:  World J Pediatr       Date:  2019-09-26       Impact factor: 2.764

Review 2.  Advances in Juvenile Dermatomyositis: Myositis Specific Antibodies Aid in Understanding Disease Heterogeneity.

Authors:  Lauren M Pachman; Amer M Khojah
Journal:  J Pediatr       Date:  2018-04       Impact factor: 4.406

3.  A high level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis.

Authors:  Q-L Peng; Y-M Zhang; L Liang; X Liu; L-F Ye; H-B Yang; L Zhang; X-M Shu; X Lu; G-C Wang
Journal:  Clin Exp Immunol       Date:  2019-12-18       Impact factor: 4.330

4.  Transcriptomes of peripheral blood mononuclear cells from juvenile dermatomyositis patients show elevated inflammation even when clinically inactive.

Authors:  Elisha D O Roberson; Rosana A Mesa; Gabrielle A Morgan; Li Cao; Wilfredo Marin; Lauren M Pachman
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

Review 5.  Consensus-based recommendations for the management of juvenile dermatomyositis.

Authors:  Felicitas Bellutti Enders; Brigitte Bader-Meunier; Eileen Baildam; Tamas Constantin; Pavla Dolezalova; Brian M Feldman; Pekka Lahdenne; Bo Magnusson; Kiran Nistala; Seza Ozen; Clarissa Pilkington; Angelo Ravelli; Ricardo Russo; Yosef Uziel; Marco van Brussel; Janjaap van der Net; Sebastiaan Vastert; Lucy R Wedderburn; Nicolaas Wulffraat; Liza J McCann; Annet van Royen-Kerkhof
Journal:  Ann Rheum Dis       Date:  2016-08-11       Impact factor: 19.103

6.  Clues to Disease Activity in Juvenile Dermatomyositis: Neopterin and Other Biomarkers.

Authors:  Amer Khojah; Gabrielle Morgan; Lauren M Pachman
Journal:  Diagnostics (Basel)       Date:  2021-12-21

7.  Juvenile Dermatomyositis: New Clues to Diagnosis and Therapy.

Authors:  Lauren M Pachman; Brian E Nolan; Deidre DeRanieri; Amer M Khojah
Journal:  Curr Treatm Opt Rheumatol       Date:  2021-02-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.